Does insurance cover GLP-1s?
Coverage depends on which of three systems pays — a commercial plan, Medicare or Medicaid — and each answers differently. Medicare trips people up most: its $50 program is designed to exclude the people whose diagnosis already qualifies them.
Does insurance cover GLP-1s for weight loss?
It depends on which of three systems you are in, and the answers differ sharply. Medicare Part D still excludes agents used for weight loss by statute; what exists instead is the Medicare GLP-1 Bridge, a CMS demonstration running from 1 July 2026 to 31 December 2027 with a $50 monthly copay — and it covers only beneficiaries who could not otherwise obtain the drug under Part D, so type 2 diabetes, moderate to severe obstructive sleep apnea or fatty liver disease rules you out of the $50, while a past heart attack or stroke is one of the conditions that rules you in. That copay does not count toward your out-of-pocket total. Medicaid is a state question: 11 of 51 programs cover a GLP-1 for obesity, each with its own criteria, and halfrx has read 48 of the 51 programs' own documents directly, naming KFF's national summary as the source for the rest. Employer plans split into two refusals that look identical at the counter: a prior-authorization denial is clinical and can be appealed, while a plan exclusion is a benefit-design decision no appeal reaches.
Does Medicare cover it?
The Part D statute excludes “agents when used for weight loss”, and that exclusion still stands. CMS proposed reinterpreting it in November 2024, recognizing obesity as a chronic disease, and did not finalize the change in April 2025, so the standard benefit does not cover a GLP-1 prescribed for weight alone.
What exists instead is the Medicare GLP-1 Bridge, a CMS demonstration running 1 July 2026 to 31 December 2027, with a $50 monthly copay for eligible Part D beneficiaries. The design is the catch: it covers only beneficiaries who could not otherwise get the drug under Part D.
Who the Bridge leaves out
- Anyone with type 2 diabetes, moderate to severe obstructive sleep apnea or fatty liver disease — Part D can cover a GLP-1 for those, so the plan is the route.
- Anyone whose Part D plan already covers a GLP-1 for them, Wegovy prescribed to reduce cardiovascular risk included. A past heart attack or stroke without that coverage is not an exclusion: with a BMI of 27 or more it is one of the qualifying conditions.
- Anyone whose use is coverable under their plan's Part D benefit — even when the drug is not on the formulary. Not being covered in practice is not the same as not being coverable on paper.
And the $50 does not count toward your true out-of-pocket total, because the demonstration sits outside the Part D payment flow.
What does my state's Medicaid do?
State by state, and the difference between states is enormous: 11 of 51 programs cover a GLP-1 for obesity at all. halfrx has read 48 of the 51 programs' own documents rather than repeating an aggregator's summary, and names KFF as the source wherever it has not.
Or by drug, where the answer is definite for every use that is not weight loss: does Medicaid cover Zepbound?, does Medicaid cover Wegovy?, does Medicaid cover Ozempic?, does Medicaid cover Mounjaro?.
What if my employer plan says it is excluded?
Two different refusals arrive at the pharmacy counter looking identical, and they need opposite responses.
A prior-authorization denial is a clinical decision: the plan covers the drug, and says this prescription has not met the criteria. That has an appeal path, a deadline, and a set of documents that usually turn it around — the letter tool builds one from your state's own criteria.
A plan exclusion is a benefit-design decision your employer made when it bought the plan. No appeal reaches it, because nobody denied anything: the benefit was never purchased. The question there is for HR, and the useful ask is the plan document language rather than a phone answer.
Manufacturer copay cards can cut a commercial copay to as little as $25, and they are barred from any government program. That is why the cash price, not the copay card, is the comparison that matters on Medicare or Medicaid — and why what a pharmacy pays is worth reading before assuming insurance is the cheaper route.
What each card actually leaves you paying, and the price when your plan excludes the drug: Zepbound with insurance, Wegovy with insurance, Ozempic with insurance, Mounjaro with insurance.
By insurer
None of these states whether you are covered — a payer is thousands of plans, and a confident answer would be wrong for most readers. Each names what actually decides it, the document that settles it, and what the drug costs if the answer is no.
Does Medicare cover Zepbound or Wegovy?
Medicare is not one plan either, but it is the one payer on this site whose rule for weight-loss drugs is written in statute rather than chosen by an employer, so its standard answer is the same for everyone.
What settles it: Your plan's Part D formulary for the non-weight indications below, and its Evidence of Coverage for whether it adds any excluded drug as a supplemental benefit.
5 plan types, the forms Medicare publishes, and the cash price →
Does UnitedHealthcare cover Zepbound or Wegovy?
UnitedHealthcare is not a plan — it is thousands of them. Most members are on an employer-sponsored plan, and whether anti-obesity medication is included at all is a choice the employer makes when buying the plan, before any clinical criteria are reached.
What settles it: The Summary Plan Description your employer issues, then your plan's Prescription Drug List. The SPD is the one that says whether the category is excluded outright.
5 plan types, the forms UnitedHealthcare publishes, and the cash price →
Does BCBS cover Zepbound or Wegovy?
Blue Cross Blue Shield is not one insurer. It is an association of independent companies, each licensed in its own territory with its own formulary — so 'does BCBS cover it' has as many answers as there are member companies, before employer choice is even considered.
What settles it: The Summary Plan Description from your employer, then the licensee's drug list for your plan.
5 plan types, the forms BCBS publishes, and the cash price →
Does Kaiser cover Zepbound or Wegovy?
Kaiser is not an insurer with a pharmacy attached — it is one organization that insures you, employs your doctor and owns the pharmacy. That removes the middleman every other payer page here is about, and replaces it with a different constraint: the formulary is set per region rather than nationally. A denial is still appealed to Kaiser first and then outside it — to independent external review on most employer and marketplace plans, an independent review entity on Medicare, a state fair hearing on Medicaid.
What settles it: The Summary Plan Description from your employer, then your region's formulary through your kp.org account.
5 plan types, the forms Kaiser publishes, and the cash price →
Does Aetna cover Zepbound or Wegovy?
Aetna is a CVS Health company, so its drug list is built by CVS Caremark and its retail and mail pharmacies sit inside the same corporate group. As with every large commercial insurer, the plan sponsor decides whether anti-obesity medication is a benefit before any clinical criterion is reached.
What settles it: The Summary Plan Description, then your plan's Caremark drug list.
5 plan types, the forms Aetna publishes, and the cash price →
Does Cigna cover Zepbound or Wegovy?
Cigna's pharmacy benefit runs through Express Scripts, which Cigna owns through Evernorth. As with every large commercial insurer, whether anti-obesity medication is a benefit at all is a plan sponsor's decision taken before any clinical criterion applies.
What settles it: The Summary Plan Description, then the specific Cigna drug list attached to the plan.
5 plan types, the forms Cigna publishes, and the cash price →
Does Humana cover Zepbound or Wegovy?
Humana is predominantly a Medicare business, which changes the answer more than any of its own policies do. For a Medicare Advantage member the drug benefit is Part D, and Part D excludes a drug prescribed for weight loss by statute rather than by plan design.
What settles it: The Evidence of Coverage for the exclusion, the Medicare drug list for the covered indications.
5 plan types, the forms Humana publishes, and the cash price →
Does TRICARE cover Zepbound or Wegovy?
TRICARE is a federal health program rather than an insurer, so two things follow that apply to no commercial plan: the drug list is a single Uniform Formulary set centrally rather than per employer, and manufacturer copay cards cannot be used at all, because federal anti-kickback rules bar a manufacturer from subsidizing a copay inside a federal program.
What settles it: The military formulary search, and your plan's referral requirements for specialty care.
5 plan types, the forms TRICARE publishes, and the cash price →
Does VA cover Zepbound or Wegovy?
The VA is not an insurer at all — it is a health system that runs its own pharmacies and publishes its own national drug list. That makes it the only payer on this site where the three things that decide the answer are separate downloadable files rather than a plan document you have to request: whether the drug is on the formulary, what level of approval it needs, and what it costs you.
What settles it: The VA National Formulary file, where both appear as INJ,SOLN marked PA-F.
Questions
- Are GLP-1s no longer covered by insurance?
- No: GLP-1s prescribed for type 2 diabetes are still covered by nearly every plan, and what has been dropped since 2024 is coverage for weight loss alone, plan by plan. North Carolina's State Health Plan ended weight-loss coverage on 1 April 2024; Massachusetts' state-employee plan followed on 1 July 2026, keeping heart disease, sleep apnea and MASH on a doctor's request and stating "Diabetes medicines are not impacted." Employers are moving both ways: KFF's 2025 survey found 43% of firms with 5,000 or more workers cover GLP-1s for weight loss, up from 28% a year earlier, but only 16% of firms with 200 to 999 workers, and heard from some that had stopped, a few tightening diabetes coverage too. Mercer counted 49% of employers with 500 or more workers in 2025, up from 44%. Pharmacy benefit managers changed which drug, not whether: CVS Caremark removed Zepbound in favor of Wegovy on 1 July 2025 and adds it back on 1 October 2026, and Express Scripts' 2026 list excludes Zepbound vials and KwikPens while keeping Wegovy and Zepbound pens. Medicaid is state by state: 11 of 51 programs cover a GLP-1 for obesity, and California's stopped on 1 January 2026. Medicare Part D still excludes weight loss by statute, so the only Medicare route, for those who qualify, is the $50 GLP-1 Bridge running to 31 December 2027. To check your own plan, look the drug up in the formulary of the pharmacy benefit manager named on your card, then ask the insurer: "Is Zepbound (or Wegovy) excluded from my plan for chronic weight management, or covered with prior authorization, and if so, under what criteria?"
- Does Medicare cover GLP-1s for weight loss?
- Not through the standard Part D benefit: the statute excludes agents used for weight loss, and the reinterpretation CMS proposed in November 2024 was not finalized in April 2025. What exists today is the Medicare GLP-1 Bridge, a CMS demonstration running from 1 July 2026 to 31 December 2027 that gives eligible Part D beneficiaries a $50 monthly copay. It deliberately covers only people who could not otherwise get the drug under Part D.
- I have a sleep apnea or heart disease diagnosis. Does that help or hurt?
- It depends which. Type 2 diabetes, moderate to severe sleep apnea and fatty liver disease exclude you from the Bridge, because Part D can cover a GLP-1 for them — Zepbound for sleep apnea is a prior authorization with the plan, even when it is not on the formulary. A previous heart attack, stroke or symptomatic peripheral artery disease works the other way: with a BMI of 27 or more it is one of the conditions that makes you eligible for the $50, unless your Part D plan already covers a GLP-1 for you, as it can for Wegovy prescribed to reduce cardiovascular risk.
- Does the $50 count toward my out-of-pocket cap?
- No. CMS states the Bridge copay does not count toward true out-of-pocket costs under a Part D plan, because the demonstration sits outside the Part D payment flow.
- Can I use a manufacturer copay card with Medicare or Medicaid?
- No. Manufacturer copay cards are barred from use with any federal healthcare program. That is why the cash price from the manufacturer, not the copay card, is the comparison that matters for anyone on Medicare or Medicaid.
- My employer plan says the drug is excluded. Is that a denial I can appeal?
- Usually not in the same way. A prior-authorization denial is a clinical decision with an appeal path; a plan exclusion is a benefit-design decision made by the employer, and the appeal is a conversation with HR or benefits rather than with the insurer. Ask for the plan document language: 'excluded' and 'requires prior authorization' look identical at the pharmacy counter and are completely different problems.
Sources: CMS, Medicare GLP-1 Bridge: Expectations and Frequently Asked Questions for Part D Sponsors, 10 June 2026; CMS, fact sheet on the Contract Year 2026 Medicare Advantage and Part D final rule, 4 April 2025, which did not finalize the anti-obesity medication proposal. State Medicaid rules are read from the program's own document where halfrx has one and from KFF's summary where it does not, each named and dated on the coverage page. On plans dropping weight-loss coverage: CVS Caremark, formulary update, 27 June 2025; CVS Caremark, Zepbound returning 1 October 2026, 28 May 2026; Express Scripts, 2026 National Preferred Formulary exclusions, revised 1 July 2026; Massachusetts Group Insurance Commission, GLP-1 coverage update, 8 June 2026; North Carolina Department of State Treasurer, 22 April 2024; KFF, 2025 Employer Health Benefits Survey, 22 October 2025; Mercer, National Survey of Employer-Sponsored Health Plans, 17 November 2025. Information only, not medical or insurance advice.
The law behind the answers here
What a plan chooses and what a statute forbids are different questions. These are the documents behind the second.
- Social Security Act §1927(d)(2), Office of the Law Revision Counsel — The statute itself, listing “agents when used for anorexia, weight loss, or weight gain” among the drugs a program may exclude.
- Manufacturer safeguards may not prevent copayment coupon use for Part D drugs, HHS Office of Inspector General — Why a manufacturer copay card cannot be used with a federal program, from the office that enforces it.
- Weight-loss drugs, Medicare.gov — Medicare's own page on what it does and does not cover for weight loss.